Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis.

Citation data:

Journal of immunology (Baltimore, Md. : 1950), ISSN: 0022-1767, Vol: 166, Issue: 10, Page: 5878-81

Publication Year:
Usage 9
Abstract Views 7
Full Text Views 1
Link-outs 1
Captures 21
Readers 21
Citations 40
Citation Indexes 40
Repository URL:
Christopher A. Hunter; Duonan Yu; Cam V. Ngo; Cinzia Sevignani; Michael Goldschmidt; Andrei Thomas-Tikhonenko; Michael Gee; William F. Lee; Sydney Evans; Tatyana V. Golovkina
The American Association of Immunologists
Immunology and Microbiology; Animal; Cell-Division; Cytotoxicity-Immunologic; Endothelium-Vascular; Immunity-Natural; Melanoma-Experimental; Mice; Mice-Inbred-C57BL; Mice-SCID; Necrosis; Neoplasm-Transplantation; Neovascularization; SUPPORT-U-S-GOVT-P-H-S; Toxoplasmosis-Animal
article description
The ability of various infections to suppress neoplastic growth has been well documented. This phenomenon has been traditionally attributed to infection-induced concomitant, cell-mediated antitumor immunity. We found that infection with Toxoplasma gondii effectively blocked neoplastic growth of a nonimmunogenic B16.F10 melanoma. Moreover, this effect was independent of cytotoxic T or NK cells, production of NO by macrophages, or the function of the cytokines IL-12 and TNF-alpha. These findings suggested that antitumor cytotoxicity was not the primary mechanism of resistance. However, infection was accompanied by strong, systemic suppression of angiogenesis, both in a model system and inside the nascent tumor. This suppression resulted in severe hypoxia and avascular necrosis that are incompatible with progressive neoplastic growth. Our results identify the suppression of tumor neovascularization as a novel mechanism critical for infection-induced resistance to tumors.